Fludarabine

For research use only.

Catalog No.S1491 Synonyms: FaraA, Fludarabinum

66 publications

Fludarabine Chemical Structure

Molecular Weight(MW): 285.23

Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells. Fludarabine induces apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 126 In stock
USD 97 In stock
USD 310 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Fludarabine has been cited by 66 publications

Purity & Quality Control

Choose Selective STAT Inhibitors

Biological Activity

Description Fludarabine is a STAT1 activation inhibitor which causes a specific depletion of STAT1 protein (and mRNA) but not of other STATs. Also a DNA synthesis inhibitor in vascular smooth muscle cells. Fludarabine induces apoptosis.
Targets
STAT1 [4]
(Vascular smooth muscle cells)
In vitro

Fludarabine efficiently inhibits the proliferation of RPMI 8226 cells with IC50 of 1.54 μg/mL. The IC50 of Fludarabine against MM.1S and MM.1R cells is 13.48 μg/mL and 33.79 μg/mL, respectively. In contrast, U266 cells are resistant to Fludarabine with IC50 of 222.2 μg/mL. Fludarabine treatment results in increased number of cells in the G1 phase of cell cycle, accompanied with a concomitant reduction of cells at the S phase of cell cycle in a time-dependent manner. Fludarabine induces a cell cycle block and triggers apoptosis in MM cells. Fludarabine triggers time-dependent cleavage of caspase-8, -9, and -3, -7, followed by PARP cleavage. Fludarabine increases expression of Bax in a time-dependent fashion, while the expression of Bak doesn't change. After exposure to Fludarabine for 12 hours, RPMI 8226 cells shows a loss of membrane potential with 61.05% of the cells expressing low fluorescence of rhodamine 123 compared with 8.62% of cells in untreated control. [1] To enhance solubility, Fludarabine is formulated as the monophosphate (F-ara-AMP, fudarabine), which is instantaneously and quantitatively dephosphorylated to the parent nucleoside upon intravenous infusion. Inside the cells rephosphorylation occurs which leads to fuoroadenine arabinoside triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. [2] Fludarabine can also induce pro-inflammatory stimulation of monocytic cells, as evaluated by increased expression of ICAM-1 and IL-8 release. [3] Fludarabine does not affect the growth of ovarian cancer cell lines, whereas it induces marked and dose-dependent inhibition of proliferation in melanoma cell lines. [4] Fludarabine induces significant reduction of STAT-1 phosphorylation, whereas it does not change JAK2 activation. Interestingly, Fludarabine does not significantly affect the phosphorylation of these three STAT proteins. Fludarabine (1.5 mg) significantly prevents STAT-1 phosphorylation and also reduces the increased amount of this protein. No significant changes are demonstrated in JAK2 phosphorylation at 2 days, but Fludarabine inhibits JAK2-increased expression at 7 days. Fludarabine specifically inhibits STAT-1 activation without affecting other STAT proteins and consequently diminishes VSMC proliferation. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  M1ToTGZ2dmO2aX;uJGF{e2G7 MX6yNEDPxE1? NUHlTINDOjRiaB?= NYTYUWltcW6qaXLpeJMh\XiycnXzd4lwdiCxZjDJSG8> M3fGV|I2QTRyN{Gy
MV-4-11 NWjlR4NISXCxcITvd4l{KEG|c3H5 MVmyMlUh|ryP MoeyOFghcA>? MojKbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= NWLjO4JxOjVzMUG1PFM>
THP-1 NUf0VJN[SXCxcITvd4l{KEG|c3H5 MWSyMlUh|ryP MXG0PEBp M1rIcolv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 NWflcYlZOjVzMUG1PFM>
MOLM 13 M1\KSWFxd3C2b4Ppd{BCe3OjeR?= MX[yMlUh|ryP MXy0PEBp MkHabY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= NGfRb4MzPTFzMUW4Ny=>
KBM3/Bu2506 NFvndJBCeG:ydH;zbZMhSXO|YYm= NV7xcGg3Oi53IN88US=> M4nWW|Q5KGh? M2LaNYlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 MkXGNlUyOTF3OEO=
Nalm-6 M{nyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTDTWM2OD1zODFOwG0> NVOxNWhXOjVyNkGxNFE>
Reh MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmf1TWM2OD1|MDFOwG0> M1:0[FI2ODZzMUCx
U2937 M{e5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\jZ2dKSzVyPUG2JO69VQ>? NGD0Sm0zPTB4MUGwNS=>
Mec-1 Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnrRoRbUUN3MP-8olUxOCEQvF2= NYfP[YRMOjVyNkGxNFE>
RPMI-8226 MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33ETWlEPTB;NUCwJO69VQ>? NUO2cphmOjVyNkGxNFE>
Molt-4 NW\VW5lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF6MDFOwG0> NVnoUpdKOjVyNkGxNFE>
Nalm-6-FluR MlzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[yTWM2OD1{NUCg{txO NInUT5MzPTB4MUGwNS=>
Raji  MoDySpVv[3Srb36gRZN{[Xl? Mo\kN:Kh|ryP MWSyOE81QC95MjDo Mom0bY5lfWOnczDhZ4N2dXWuYYTpc45{KG:oIIC1N{wheDZ|IHHu[EBxPzQEoB?= MnjjNlQ6PDB4OUW=
PBMC NXLzXVhzTnWwY4Tpc44hSXO|YYm= MmC5OVAwOTByIN88US=> M2fZV|I1KGh? M3jhVGROW09? MkjibY5pcWKrdIOgV3RCXDFicHjvd5Bpd3K7bHH0bY9v MUGyOFkyOTh5Mh?=
MDA-231 MWnGeY5kfGmxbjDBd5NigQ>? M3roUFExOCEQvF2= M1LoVFI1KGh? NY\vW2sxTE2VTx?= NHPNdlVl\WO{ZXHz[ZMhUUSRIHX4dJJme3Orb36= NXTY[pVLOjR7MUG4O|I>
624.38mel  NG[0Zo9HfW6ldHnvckBCe3OjeR?= Mn\pOVAh|ryP NIXzTHgzPCCq MXvEUXNQ MVHk[YNz\WG|ZYOgTWRQKGW6cILld5Nqd25? NHnkeWIzPDlzMUi3Ni=>
MDA-231 Ml60SpVv[3Srb36gRZN{[Xl? Ml\6OVAuOjByIN88US=> NUPvSGtGOjRiaB?= NHrBfXJFVVOR M4TMdolvcGmkaYTzJGlFVyCjY4Tpeol1gSCrbnTldIVv\GWwdHz5JI9nKG2UTlGgcIV3\Wy| MYOyOFkyOTh5Mh?=
624.38mel  MUTGeY5kfGmxbjDBd5NigQ>? M4jUfVUxNTJyMDFOwG0> NIrCRmszPCCq MmTFSG1UVw>? NGH1W3RqdmirYnn0d{BKTE9iYXP0bZZqfHliaX7k[ZBmdmSnboTsfUBw\iCvUl7BJIxmfmWucx?= MnraNlQ6OTF6N{K=
HMECs MXXGeY5kfGmxbjDBd5NigQ>? MVyxNFDDqM7:TdMg NI\ab2Y{PsLiaB?= MmPZbY5pcWKrdIOgTWZP|rQEoHHu[EBNWFNiaX7keYNm\CCVVFHUNUBxcG:|cHjvdplt[XSrb36gZY5lKEmURkGg[ZhxemW|c3nvci=> MViyOFIyOTN{Nx?=
HMECs  M{e1NGZ2dmO2aX;uJGF{e2G7 MWGxNFDDqM7:TdMg Mn:3N|bDqGh? MVjpcohq[mm2czDJSm7PucLibXXkbYF1\WRicHjvd5Bpd3K7bHH0bY9vKG:oIGPURXQyKGGwZDDTWGFVOyxiYoX0JI5wfCCxZjDTWGFVOg>? NXX2TXI5OjR{MUGzNlc>
BJAB M1\YW2Fxd3C2b4Ppd{BCe3OjeR?= NVTudVBnPcLizszN M2CwZVI1KGh? NEDCN|NqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MlvNNlQxPTdzNEe=
I-83 NVi4OYdTSXCxcITvd4l{KEG|c3H5 MYm1xsDPxE1? MkPmNlQhcA>? MWjpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M{KwXVI1ODV5MUS3
NALM6 NIXaOJlCeG:ydH;zbZMhSXO|YYm= NWnHbnd3PcLizszN NULscGpPOjRiaB?= M{PTbIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NIXpS2czPDB3N{G0Oy=>
DU-145 NHjMVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXiOlNbOC1zMDFOwIcwdWx? MVu0PEBpyqB? Mn7tbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHX5V4wzOzd|NEixOS=>
Nalm-6 NVq3e|hLTnWwY4Tpc44hSXO|YYm= MWexNOKh|ryP NGD3PHgyNzJxNDDo MkfSbY5lfWOnczDheZRweGijZ4m= MlqxNlM3QDF{MkO=
Reh M1vW[WZ2dmO2aX;uJGF{e2G7 MV:xNOKh|ryP MornNU8zNzRiaB?= NYXhSpJjcW6mdXPld{BifXSxcHjh[5k> MoHnNlM3QDF{MkO=
Nalm-6 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX21UoxZUUN3MDFijNwyOOLCid88US=> NXq1RZFFOjN4OEGyNlM>
Reh NFu1SFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljCTWM2OCEkiMyxNQKBkc7:TR?= MWOyN|Y5OTJ{Mx?=
HEC1A MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXYbpVPOTByLUWwNEDPxE1? M1jSUVI1KGh? Mkm4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWqyN|U6PTZ7Nx?=
AN3CA MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfKTpQyODBvNUCwJO69VQ>? MYOyOEBp NV63ZlRVcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXGyN|U6PTZ7Nx?=
HEC50B MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHSNVAxNTVyMDFOwG0> M3y1S|I1KGh? MXzpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> MUSyN|U6PTZ7Nx?=
HEC1A M{DsOWFxd3C2b4Ppd{BCe3OjeR?= Mm\NNlAwOTByIN88US=> MYeyOEBp M2rueolv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NG\EVZMzOzV7NU[5Oy=>
AN3CA NYnBT5lsSXCxcITvd4l{KEG|c3H5 MYiyNE8yODBizszN NFjBWpMzPCCq NX7VS3c1cW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4r3NlI{PTl3Nkm3
HEC50B MV;BdI9xfG:|aYOgRZN{[Xl? MkHVNlAwOTByIN88US=> MW[yOEBp MVnpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= Mnv0NlM2QTV4OUe=
EHEB MV7BdI9xfG:|aYOgRZN{[Xl? NIXPPGk1OCEQvF2= Ml3jNlQhcA>? NWjBdFRRcW6mdXPld{BieG:ydH;zbZM> NH;QW3AzOzR7N{C3OS=>
A549 NYr1VWlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;pemR1UUN3ME2xOU44yrF{LkigxtVO NFHxZWYzOzN5N{G5Ni=>
A549 GAPDH-deficient MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr1TWM2OD1zOD61xtEzNjNiwsXN MXWyN|M4PzF7Mh?=
CLL  MUjBdI9xfG:|aYOgRZN{[Xl? NY\0NWY4OTBizszNxsA> MV:yOE06PiCq MnS3bY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=> MX:yNlIxPzZ6Nh?=
MEC1 NYfrVpJNSXCxcITvd4l{KEG|c3H5 NUXpToNHOTBywrFOwG0> M{f4OFczKGh? NF\zd5FqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 NUPZVnRXOjJzM{K5O|M>
U937  NVL4dVd7SXCxcITvd4l{KEG|c3H5 M2X0PFAvQCEQvF2= NXu0dpRiPC12ODDo NGS4RZVqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> NWC3VYlSOjJyN{S3NFA>
U937  NFHIT4hCeG:ydH;zbZMhSXO|YYm= MnrWNUDPxE1? Mkm1PVYhcA>? MmPobY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= MWmyNlAzOzV{Mx?=
Daudi M3nKcGFxd3C2b4Ppd{BCe3OjeR?= NUDZdHZ5OjBizszN NVvwdIhoQTZiaB?= NXTod5g6cW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk> MorWNlIxOjN3MkO=
J45.01 NETLUGVCeG:ydH;zbZMhSXO|YYm= M3jZSlEh|ryP MXu5OkBp MVzpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= MkT6NlIxOjN3MkO=
RPMI 8226 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi0VWFIUUN3ME2yOU46yqEEsdMgN{44KM7:TR?= MWOyNVk1QDJ4NB?=
CEM NFr2PGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJwNNMgxtHDqDBwNDFOwG0> NYXHTHVUOjF7NEiyOlQ>
Raji Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwNEhCpOKyyqByLkC0JO69VQ>? NEPxOm8zOTl2OEK2OC=>
U937 NEW2XWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPvTWM2OD1yLkK0xsDDucLiMD6wOEDPxE1? M{XjcVIyQTR6Mk[0
K562 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDWTWM2OD1yLkS0xsDDucLiMD6wOUDPxE1? NW[3S|R6OjF7NEiyOlQ>
NALM-6 M4XiZ2Fxd3C2b4Ppd{BCe3OjeR?= NFq4SYgyOCEQvF5CpC=> M1HjNFI1KGh? M{XVbIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3zp[4h1dHl? MojjNlE3QTl|OEO=
JMV-3 MlLpRZBweHSxc3nzJGF{e2G7 NFnLUWQyOCEQvF5CpC=> NIDGZVYzPCCq MXrpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOuaXfoeIx6 NFLaZ2ozOTZ7OUO4Ny=>
EHEB M2PvdWZ2dmO2aX;uJGF{e2G7 NYXYeXlSPS13MDFOwG0> M{PtXVI1KGh? MWHk[YNz\WG|ZYOgdFIyKGW6cILld5Nqd25ic3nncolncWOjboTsfS=> MlfDNlEyPjh|OUG=
JVM-2  NXOwW41lTnWwY4Tpc44hSXO|YYm= NVzlS2RLOzBizszN MlfPNlQhcA>? NYq4U2s2\GWlcnXhd4V{KHB{MTDlfJBz\XO|aX;u NHnuPWczOTF4OEO5NS=>
KBM3/Bu2506 M2HJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITXZ2RKSzJyPUCuOlchyrWP NVi5WXY5OjB7M{O1NFk>
KBM3/Bu2506 NYDNd4xjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[wMlYh|ryP M4\6W|I1KGh? MVnpcoNz\WG|ZYOgeIhmKGOnbHyg[pJi[3Srb36gbY4hWy2yaHHz[S=> MX[yNFk{OzVyOR?=
MDA-MB-231 MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P6ZmlEPTB;ND6wJO69VQ>? M1f4UFIxPDR5M{mw
MCF-7 NUnHfZFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXlcZBKSzVyPUG1MlAh|ryP NFjkSpczODR2N{O5NC=>
HLE-B3  M4n6N2Z2dmO2aX;uJGF{e2G7 MoHsNlUh|ryP NH2zUmY1QCCq NUS1TVFV[myxY3vzJGlHVi4Qs,MAl4lv\HWlZXSgV3RCXDFicHjvd5Bpd3K7bHH0bY9vKGGwZDDJSG8h\XiycnXzd4lwdg>? M2KxdlIxPDN3MUW4
K562 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;6OVM4OiCq NWLw[5d[UUN3ME2zMlMhdk1? MUmyNFMxPzF7OB?=
BW-225 MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S2dWlEOjB;MT6zO{DEnzFy4pkSPOKh|ryPwrC= NFXJfGwyQDZ4MUO4NC=>
OH-65 MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP3fnhoUUN{ME2xMlM4KMPZMUFijLI5yqEQvF5CpC=> MnPkNVg3PjF|OEC=
GR-145 NEe3S2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfNPWZKSzJyPUKuO|Qhy5diMUFijLI5KCEQvF5CpC=> M{HSfVE5PjZzM{iw
A549 NIrqfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrS[lBKSzJyPUWuOFghy5diMUFijLI5KM7:TdMg NXH3T4hYOTh4NkGzPFA>
CaSki  M4Xtcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITJeIxKSzJyPUGuN|chy5diMUFijLI4KM7:TdMg NYqyWIFyOTh4NkGzPFA>
ZMK-1 NH;ndWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e5PGlEOjB;MT6zO{DEnyBzMPMIllYh|ryPwrC= M2TwSlE5PjZzM{iw
SKW6.4 MnTORZBweHSxc3nzJGF{e2G7 MnTNNE4xOS1zMDFOwG0> NYXBfmRGOjRxNEigbC=> NE\4cIRqdmS3Y3XzJINmdGxiZHXheIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= M1XQXFE5ODl{M{Sw
RPMI 8226 Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYiyOEBp NHvVZYJKSzVyPUGuOVTDqM7:TR?= MUSxO|k4PjF6Nh?=
MM.1S NWr5N|g6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rYT|Q5KGh? NVHPepJSUUN3ME2xN{41QMLizszN M1O2S|E4QTd4MUi2
MM.1R M3\3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlS0OFghcA>? MUDJR|UxRTN|Lke5JO69VQ>? MWexO|k4PjF6Nh?=
U937 MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rZfmlEPTB;MzyyNFAhyrFiNU[wJI5O MmPJNVU6OzB|NkG=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
procaspase-9 / procaspase-3; 

PubMed: 27223263     


Procaspase-9 and procaspase-3 were analyzed by Western blot in CLL cells from three patients after a 48 h-incubation in the absence or presence of 3 μM aphidicolin (APC) with or without fludarabine at 0.3 and 1 μM. β-Actin served as a loading control.

p-p53 / p53; 

PubMed: 27223263     


(A–B) CLL cells from 3 different patients were incubated for 24 h with fludarabine at the indicated concentrations in the absence or presence of 3 μM aphidicolin (APC). Phosphorylation of p53 at Ser-15 and total p53 were analyzed by Western blot. Data sho䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒

STAT1; 

PubMed: 26677135     


Representative western blot analysis of STAT1 in RAW 264.7 cells treated with STAT1 inhibitor fludarabine (Flu) for 24 h.

27223263 26677135
Immunofluorescence
α-SMA / Vimentin; 

PubMed: 28322315     


FLU (50 μM) reduces the expression of α-SMA and Vimentin protein in primary mouse activated HSCs (Hepatic Stellate Cells).

28322315
Growth inhibition assay
Cell viability ; 

PubMed: 24956101     


CLL cells RPMI/0.1% FBS were cultured on 0.5% BSA or 150 nM MMP-9 for 1 h prior to adding the indicated concentrations of fludarabine (Fluda). After 48 h (Fluda) cell viability was determined by flow cytometry using FITC-Annexin V and PI.

24956101
In vivo Tumors treated with PBS grow rapidly to approx-imately 10-fold their initial volume in 25 day, whereas, the tumors in the Fludarabine at 40 mg/kg increase less than 5-fold. A significant antitumor effect of 40 mg/kg Fludarabine on RPMI8226 tumor growth is demonstrated. RPMI8226 tumors treated with 40 mg/kg Fludarabine at day 10 increase apoptotic nuclei. Fludarabine is effective in suppressing RPMI8226 myeloma xenografts in SCID mice. [1]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: Dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines
  • Concentrations: 2 μg/mL
  • Incubation Time: 24 hours
  • Method:

    After treated with Fludarabine or control, dexamethasone-sensitive (MM.1S) and -resistant (MM.1R) human MM cell lines, RPMI8226 and U266 cell lines (5 × 105 cells) are washed twice in phosphate-buffered saline (PBS) and fixed with 70% ice-cold ethanol, then centrifuged and suspended in PBS containing 100 μg/mL RNase A. After incubated for 30 minutes at 37 ºC, samples are resuspended in 25 μg/mL propidium iodide. Flow cytometry is performed on a FACSCalibur automated system. Apoptosis is determined by Annexin V-FITC apoptosis detection kit, according to the manufacturer's instructions. For TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling) assay, cells are analyzed by flow cytometry using the in situ cell death detection kit.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Severe combined immunodeficient (SCID) mice bearing RPMI 8226 cells
  • Dosages: 40 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL (suspension)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 285.23
Formula

C10H12FN5O4

CAS No. 21679-14-1
Storage powder
in solvent
Synonyms FaraA, Fludarabinum
Smiles NC1=NC(=NC2=C1N=C[N]2C3OC(CO)C(O)C3O)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03832127 Not yet recruiting Drug: 18F-Fludarabine Myeloma Nantes University Hospital|Cyceron April 1 2019 Phase 1
NCT03348033 Enrolling by invitation Biological: Chronic Myeloid Leukemia + NK cell Chronic Myeloid Leukemia Hospital de Clinicas de Porto Alegre March 2019 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • Answer:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STAT Signaling Pathway Map

Related STAT Products

Tags: buy Fludarabine | Fludarabine supplier | purchase Fludarabine | Fludarabine cost | Fludarabine manufacturer | order Fludarabine | Fludarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID